This HTML5 document contains 88 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n14http://linked.opendata.cz/resource/drugbank/drug/DB00655/identifier/pubchem-substance/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00655/identifier/kegg-drug/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00655/identifier/iuphar/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00655/identifier/drugbank/
n5http://linked.opendata.cz/resource/AHFS/
n7http://linked.opendata.cz/resource/drugbank/company/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00655/identifier/guide-to-pharmacology/
n27http://linked.opendata.cz/resource/drugbank/mixture/
n22http://bio2rdf.org/drugbank:
n23http://linked.opendata.cz/resource/drugbank/drug/DB00655/identifier/chemspider/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00655/identifier/chebi/
admshttp://www.w3.org/ns/adms#
n10http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n28http://linked.opendata.cz/resource/drugbank/drug/DB00655/identifier/wikipedia/
n11http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00655/identifier/pharmgkb/
n6http://linked.opendata.cz/resource/drugbank/property/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00655/identifier/kegg-compound/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00655/identifier/bindingdb/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00655/identifier/pdb/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/resource/drugbank/drug/DB00655/identifier/pubchem-compound/
n8http://linked.opendata.cz/resource/atc/
n4http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00655
rdf:type
n3:Drug
n3:description
Estrone, one of the major mammalian estrogens, is an aromatized C18 steroid with a 3-hydroxyl group and a 17-ketone. It is produced in vivo from androstenedione or from testosterone via estradiol. It is produced primarily in the ovaries, placenta, and in peripheral tissues (especially adipose tissue) through conversion of adrostenedione. Estrone may be further metabolized to 16-alpha-hydroxyestrone, which may be reduced to estriol by estradiol dehydrogenase.
n3:generalReferences
# Miyoshi Y, Tanji Y, Taguchi T, Tamaki Y, Noguchi S: Association of serum estrone levels with estrogen receptor-positive breast cancer risk in postmenopausal Japanese women. Clin Cancer Res. 2003 Jun;9(6):2229-33. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12796390 # Kajta M, Lason W, Bien E, Marszal M: Neuroprotective effects of estrone on NMDA-induced toxicity in primary cultures of rat cortical neurons are independent of estrogen receptors. Pol J Pharmacol. 2002 Nov-Dec;54(6):727-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12866733
n3:group
approved
n3:halfLife
19 hours
n3:indication
For management of perimenopausal and postmenopausal symptoms.
n3:manufacturer
n7:271B62C3-363D-11E5-9242-09173F13E4C5 n7:271B62C2-363D-11E5-9242-09173F13E4C5 n7:271B62C1-363D-11E5-9242-09173F13E4C5
owl:sameAs
n10:DB00655 n22:DB00655
dcterms:title
Estrone
adms:identifier
n14:46505916 n15:PA449512 n16:5870 n17:D00067 n18:E3G n19:2818 n20:C00468 n21:2818 n23:5660 n24:DB00655 n25:17289 n26:17263 n28:Estrone
n3:mechanismOfAction
Estrogens enter the cells of responsive tissues (e.g. female organs, breasts, hypothalamus, pituitary) where they interact with estrogen receptors. Hormone-bound estrogen receptors dimerize, translocate to the nucleus of cells and bind to estrogen response elements (ERE) of genes. Binding to ERE alters the transcription rate of affected genes. Estrogens increase the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) release from the anterior pituitary.
n3:packager
n7:271B62B8-363D-11E5-9242-09173F13E4C5 n7:271B62B9-363D-11E5-9242-09173F13E4C5 n7:271B62B7-363D-11E5-9242-09173F13E4C5 n7:271B62BC-363D-11E5-9242-09173F13E4C5 n7:271B62BD-363D-11E5-9242-09173F13E4C5 n7:271B62BA-363D-11E5-9242-09173F13E4C5 n7:271B62BB-363D-11E5-9242-09173F13E4C5 n7:271B62C0-363D-11E5-9242-09173F13E4C5 n7:271B62BE-363D-11E5-9242-09173F13E4C5 n7:271B62BF-363D-11E5-9242-09173F13E4C5
n3:synonym
follicular hormone Estronum Oestrone Estrona Estrone Folliculin 3-Hydroxy-1,3,5(10)-estratrien-17-one
n3:toxicity
Symptoms of overdose include nausea and vomiting. Estrogen related side effects include nausea, breast tenderness, fluid retention and edema, headaches and/or migraines, chloasma and poor contact lens fit. Estrogen hormone deficiency is associated with breakthrough bleeding, hypomenorrhea, irritability, depression and menopausal symptoms. Withdrawal bleeds may occur in females.
n4:hasAHFSCode
n5:68-16-04 n5:92-02-00%2A
n3:mixture
n27:271B62B6-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
> 95%
n3:synthesisReference
Seiichi Takano, Kunio Ogasawara, "Method for producing (+)-estrone derivatives." U.S. Patent US5424462, issued January, 1965.
n3:IUPAC-Name
n6:271B62CA-363D-11E5-9242-09173F13E4C5
n3:InChI
n6:271B62D0-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n6:271B62CF-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n6:271B62CC-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n6:271B62CD-363D-11E5-9242-09173F13E4C5
n3:SMILES
n6:271B62CE-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n6:271B62E0-363D-11E5-9242-09173F13E4C5 n6:271B62C8-363D-11E5-9242-09173F13E4C5
n3:logP
n6:271B62C6-363D-11E5-9242-09173F13E4C5 n6:271B62E3-363D-11E5-9242-09173F13E4C5 n6:271B62C9-363D-11E5-9242-09173F13E4C5
n3:logS
n6:271B62C7-363D-11E5-9242-09173F13E4C5 n6:271B62E4-363D-11E5-9242-09173F13E4C5
n4:hasATCCode
n8:G03CA07 n8:G03CC04
n3:H-Bond-Acceptor-Count
n6:271B62D6-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n6:271B62D7-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n6:271B62D1-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n6:271B62D2-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n6:271B62D4-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n6:271B62D3-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n6:271B62D5-363D-11E5-9242-09173F13E4C5
n3:absorption
43%
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
53-16-7
n3:category
n3:containedIn
n11:271B62C5-363D-11E5-9242-09173F13E4C5 n11:271B62C4-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n6:271B62DC-363D-11E5-9242-09173F13E4C5
n3:Boiling-Point
n6:271B62E2-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n6:271B62DE-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n6:271B62DF-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n6:271B62E1-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n6:271B62DB-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n6:271B62DA-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n6:271B62DD-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n6:271B62CB-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n6:271B62D8-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n6:271B62D9-363D-11E5-9242-09173F13E4C5